Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Publisher Correction: Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.

Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA.

Nat Biomed Eng. 2018 Sep;2(9):707. doi: 10.1038/s41551-018-0299-6.

PMID:
31015683
2.

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.

Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA.

Nat Biomed Eng. 2018 Nov;2(11):822-830. doi: 10.1038/s41551-018-0279-x. Epub 2018 Aug 20. Erratum in: Nat Biomed Eng. 2018 Sep;2(9):707.

3.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

4.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

5.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17.

6.

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K.

J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745.

7.

Altered antisense-to-sense transcript ratios in breast cancer.

Maruyama R, Shipitsin M, Choudhury S, Wu Z, Protopopov A, Yao J, Lo PK, Bessarabova M, Ishkin A, Nikolsky Y, Liu XS, Sukumar S, Polyak K.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2820-4. doi: 10.1073/pnas.1010559107. Epub 2010 Nov 22.

8.

Gene expression profiling of human breast tissue samples using SAGE-Seq.

Wu ZJ, Meyer CA, Choudhury S, Shipitsin M, Maruyama R, Bessarabova M, Nikolskaya T, Sukumar S, Schwartzman A, Liu JS, Polyak K, Liu XS.

Genome Res. 2010 Dec;20(12):1730-9. doi: 10.1101/gr.108217.110. Epub 2010 Nov 2.

9.

Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.

Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K.

Clin Cancer Res. 2010 Feb 1;16(3):876-87. doi: 10.1158/1078-0432.CCR-09-1532. Epub 2010 Jan 26.

10.

Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies.

Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M.

Lab Invest. 2009 Aug;89(8):857-66. doi: 10.1038/labinvest.2009.54. Epub 2009 Jun 1.

11.

Epigenetic patterns of embryonic and adult stem cells.

Bloushtain-Qimron N, Yao J, Shipitsin M, Maruyama R, Polyak K.

Cell Cycle. 2009 Mar 15;8(6):809-17. Epub 2009 Mar 26.

PMID:
19229128
12.

Cell type-specific DNA methylation patterns in the human breast.

Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, Sukumar S, Parsons R, Richardson AL, Stampfer MR, Gelman RS, Nikolskaya T, Nikolsky Y, Polyak K.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14076-81. doi: 10.1073/pnas.0805206105. Epub 2008 Sep 9.

13.

The epithelial-mesenchymal transition generates cells with properties of stem cells.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.

Cell. 2008 May 16;133(4):704-15. doi: 10.1016/j.cell.2008.03.027.

14.

No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas.

Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG.

Nat Genet. 2008 May;40(5):650-5. doi: 10.1038/ng.117. Epub 2008 Apr 13.

15.

The cancer stem cell hypothesis: in search of definitions, markers, and relevance.

Shipitsin M, Polyak K.

Lab Invest. 2008 May;88(5):459-63. doi: 10.1038/labinvest.2008.14. Epub 2008 Mar 31. Review.

16.

The genomic landscapes of human breast and colorectal cancers.

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B.

Science. 2007 Nov 16;318(5853):1108-13. Epub 2007 Oct 11.

17.

Molecular definition of breast tumor heterogeneity.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K.

Cancer Cell. 2007 Mar;11(3):259-73.

18.

Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM.

Cancer Cell. 2005 Jun;7(6):533-45.

19.
20.

Phosphorylation of Minor Lipids of Human Milk Tightly Bound to Secretory Immunoglobulin A.

Gorbunov DV, Semenov DV, Shipitsin MV, Kit YY, Kanyshkova TG, Buneva VN, Nevinsky GA.

Russ J Immunol. 2000 Oct;5(3):267-278.

PMID:
12687181
21.

Ral-GTPase influences the regulation of the readily releasable pool of synaptic vesicles.

Polzin A, Shipitsin M, Goi T, Feig LA, Turner TJ.

Mol Cell Biol. 2002 Mar;22(6):1714-22.

22.

Unusual phospholipids of human breast milk.

Gorbunov DA, Semenov DV, Shipitsin MV, Nevinsky GA.

Dokl Biochem Biophys. 2001 Mar-Apr;377:62-4. No abstract available.

PMID:
11712151
23.

An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity.

Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG, Feig LA.

EMBO J. 2000 Feb 15;19(4):623-30.

24.

Phosphorylation of lipids tightly bound to secretory immunoglobulin A in antibody fractions from human breast milk possessing protein kinase activity.

Kit YY, Shipitsin MV, Semenov DV, Richter VA, Nevinsky GA.

Biochemistry (Mosc). 1998 Jun;63(6):719-24.

PMID:
9668213

Supplemental Content

Loading ...
Support Center